Although there has been little prior research on ZNF217 in AML, we found that ZNF217 expression is higher in AML patient samples than in healthy human HSPCs, additionally, higher ZNF217 expression correlates with a poorer prognosis. The gene discussed is ZNF217; the disease is acute myeloid leukemia.